Canada markets close in 2 hours 5 minutes

Defence Therapeutics Inc. (DTC.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
2.12000.0000 (0.00%)
As of 11:49AM EDT. Market open.
Full screen
Previous Close2.1200
Open2.1700
Bid2.1000 x N/A
Ask2.1500 x N/A
Day's Range2.1200 - 2.1700
52 Week Range1.6500 - 8.1500
Volume17,597
Avg. Volume9,213
Market Cap77.623M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1950
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.02
  • Newsfile

    Defence Therapeutics Receives U.S. Patent Covering Its ADC Platform Technology

    Vancouver, British Columbia--(Newsfile Corp. - August 8, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"), is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted Defence Therapeutics Inc. the U.S. patent no. 11,352,437.This

  • Newsfile

    Breakthrough Discovery: AccuTOX(TM) Effectively Kills Cancer Cells by Directly Eliciting DNA Damage

    Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the discovery of a novel DNA damaging function triggered by one of its lead compounds AccuTOXTM, which effectively elicits cell death in cancer cells.Cancer can be generally described as a s

  • Newsfile

    Defence's Accum(TM) with Antibody Drug Conjugates (ADC) in Development Against Cancer

    Vancouver, British Columbia--(Newsfile Corp. - July 5, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to provide an update on its ADC programs in development using Defence's AccumTM, including key in vivo studies with worldwide collaborators. The world-renowned Curie Institute, one of Defence's collabor